News

Oertli staff re-vamp

Oertli has welcomed several new employees to their recently improved Marketing and Sales department

LASIK project is underway

A recent LASIK panel symposium has revealed the progresses and plans for the LASIK Quality of Life Collaboration Project.

The presence of cataracts could influence optical coherence tomography (OCT) signal strength (SS) and peripapillary retinal nerve fibre layer (RNFL) thickness measurements

CORNEA_PROTECT®

CORNEA_PROTECT® (2% HPMC) guarantees protection and moisturization of the corneal surface during surgical procedures for up to 20 min. Also applications as a contact agent are possible.

A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.

An investigation, published in Inorganic Chemistry, has revealed that the reaction of pirenoxine (PRX) with selenite or calcium ions could be adapted as an anti-cataract agent.

Bausch + Lomb has introduced a free iPhone application that will test a patient's visual acuity and colour vision, enable them to learn more about cataracts and Crystalens and find a suitable surgeon.

Novartis has received the eagerly anticipated approval from the European Commission for Lucentis (ranibizumab) to treat visual impairment due to diabetic macular oedema (DME).

Endoscopic cyclophotocoagulation combined with pars plana vitrectomy is a safe and highly effective technique for treating elevated IOP in pseudophakic eyes.

An ongoing European multicentre study is investigating a 'ray-tracing' ablation profile for myopic LASIK using an excimer laser. Results from patients treated by one investigator suggest superior outcomes relative to currently available ablation techniques.

Dr Claes Feinbaum investigates emerging evidence that CCT is an important predictor for the development of primary open-angle glaucoma (POAG), and that it may be relevant as a predictor of both glaucoma progression and response to IOP-lowering medication

The efficacy and safety of two doses of a fluocinolone acetonide intravitreal insert for the treatment of DME were investigated in two sham-controlled phase III studies